<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald J Wong, BA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vinod K Bhutani, MD, FAAP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven A Abrams, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth B Rand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 27, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nearly all newborn infants develop elevated bilirubin levels (ie, total serum or plasma bilirubin [TSB] &gt;1 mg/dL [17 micromol/L], which is the upper limit of normal for adults). As bilirubin levels increase, the newborn may develop visible jaundice. Newborns with severe hyperbilirubinemia (defined as TSB &gt;25 mg/dL [428 micromol/L] in term and late preterm newborns [gestational age ≥35 weeks]) are at risk for developing bilirubin-induced neurotoxicity. Other related issues are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors, clinical manifestations, and neurologic complications of neonatal hyperbilirubinemia (see  <a class="medical medical_review" href="/d/html/4994.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for hyperbilirubinemia in term and late preterm newborns (see  <a class="medical medical_review" href="/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of neonatal hyperbilirubinemia (see  <a class="medical medical_review" href="/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"</a> and  <a class="medical medical_review" href="/d/html/121592.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Escalation of care"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperbilirubinemia in preterm infants (GA &lt;35 weeks) (see  <a class="medical medical_review" href="/d/html/5037.html" rel="external">"Unconjugated hyperbilirubinemia in preterm infants &lt;35 weeks gestation"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conjugated (direct) hyperbilirubinemia in neonates (see  <a class="medical medical_review" href="/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a>).</p><p></p><p class="headingAnchor" id="H710863534"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign neonatal hyperbilirubinemia</strong> is a transient and normal increase in bilirubin levels occurring in nearly all newborn infants. It has also been referred to as "physiologic" jaundice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe neonatal hyperbilirubinemia</strong> is defined as a total serum or plasma bilirubin (TSB) &gt;25 mg/dL (428 micromol/L). It is associated with an increased risk for developing bilirubin-induced neurotoxicity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extreme neonatal hyperbilirubinemia</strong> is defined as a TSB &gt;30 mg/dL (513 micromol/L). It is associated with a higher risk for developing bilirubin-induced neurologic dysfunction (BIND).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bilirubin-induced neurologic disorders (BIND) </strong>result from selective brain damage from free (unbound) bilirubin crossing the blood-brain barrier and binding to brain tissue. The spectrum of neurotoxic injury, including subtle dysfunction and acute and chronic bilirubin encephalopathy (ABE and CBE, respectively), is collectively referred to as BIND. The manifestations of BIND, ABE, and CBE are described separately. (See  <a class="medical medical_review" href="/d/html/4994.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Consequences of severe hyperbilirubinemia'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">BILIRUBIN METABOLISM</span><span class="headingEndMark"> — </span>Knowledge of the basic steps in bilirubin metabolism is essential to the understanding of the pathogenesis of neonatal hyperbilirubinemia. Bilirubin metabolism is briefly reviewed here and is discussed in detail separately  (<a class="graphic graphic_figure graphicRef121543" href="/d/graphic/121543.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/3622.html" rel="external">"Bilirubin metabolism"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Bilirubin production</span><span class="headingEndMark"> — </span>Bilirubin is a product of heme catabolism. In newborns, approximately 80 to 90 percent of bilirubin is produced during the breakdown of hemoglobin from red blood cells or from ineffective erythropoiesis. The remaining 10 to 20 percent is derived from the breakdown of other heme-containing proteins, such as cytochromes and catalase. Measurements of carbon monoxide (CO) production, such as end-tidal CO (ETCO) or carboxyhemoglobin (COHb) levels, both corrected for ambient CO (ETCOc and COHbc, respectively), can be used as indices of in vivo bilirubin production</p><p>Bilirubin is produced in two steps  (<a class="graphic graphic_figure graphicRef121543" href="/d/graphic/121543.html" rel="external">figure 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>The enzyme heme oxygenase (HO), located in all nucleated cells, catalyzes the breakdown of heme, resulting in the formation of equimolar quantities of iron, CO, and biliverdin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biliverdin then is rapidly converted to bilirubin by the enzyme biliverdin reductase. (See  <a class="medical medical_review" href="/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening", section on 'Determining follow-up and need for additional evaluation and/or treatment'</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Bilirubin clearance and excretion</span><span class="headingEndMark"> — </span>Clearance and excretion of bilirubin occur in the following subsequent steps  (<a class="graphic graphic_figure graphicRef121543" href="/d/graphic/121543.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic uptake – Circulating bilirubin bound to albumin is transported to the liver. Bilirubin then dissociates from albumin and is taken up by hepatocytes, where it is processed for excretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conjugation – In hepatocytes, the enzyme uridine diphosphogluconurate glucuronosyltransferase (UGT1A1) catalyzes the conjugation of bilirubin with glucuronic acid, producing bilirubin diglucuronides and, to a lesser degree, bilirubin monoglucuronides. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biliary excretion – Conjugated bilirubin, which is more water-soluble than unconjugated bilirubin, is secreted into the bile in an active process that depends upon canalicular transporters, and then excreted into the digestive tract  (<a class="graphic graphic_figure graphicRef52393" href="/d/graphic/52393.html" rel="external">figure 2</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enterohepatic circulation – The secreted conjugated bilirubin cannot be reabsorbed by the intestinal epithelial cells. In the adult, it is reduced to urobilin by intestinal bacterial enzymes. However, at birth an infant's gut is sterile and, subsequently, infants have far fewer bacteria in the gut, so very little, if any, conjugated bilirubin is reduced to urobilin. In the infant, beta-glucuronidase in intestinal mucosa deconjugates the conjugated bilirubin. The unconjugated bilirubin can then be reabsorbed through the intestinal wall and recycled into the circulation, a process known as the enterohepatic circulation of bilirubin.</p><p></p><p class="headingAnchor" id="H5"><span class="h1">BENIGN NEONATAL HYPERBILIRUBINEMIA</span><span class="headingEndMark"> — </span>Benign neonatal hyperbilirubinemia (also previously referred to as "physiologic jaundice") results in unconjugated (indirect-reacting) bilirubinemia that occurs in nearly all newborns [<a href="#rid1">1</a>]. It is a normal transitional phenomenon caused by the turnover of fetal red blood cells, the immaturity of the newborn's liver to efficiently metabolize (conjugate) bilirubin, and increased enterohepatic circulation. </p><p>Normal adult total serum or plasma bilirubin (TSB) levels are &lt;1 mg/dL, while term newborns typically have TSB levels that peak at a median of approximately 8 to 9 mg/dL because: </p><p class="bulletIndent1"><span class="glyph">●</span>Newborns have more red blood cells (hematocrit between 50 to 60 percent), and fetal red blood cells have a shorter life span (approximately 85 days) than those in adults. After birth there is an increased turnover of fetal red blood cells, resulting in the production of more bilirubin. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bilirubin clearance (conjugation and excretion) is decreased in newborns, mainly due to the deficiency of the hepatic enzyme uridine diphosphogluconurate glucuronosyltransferase (UGT1A1). UGT1A1 activity in term infants at seven days of age is approximately 1 percent of that of the adult liver and does not reach adult levels until 14 weeks of age [<a href="#rid2">2,3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is an increase in the enterohepatic circulation of bilirubin as the amount of unconjugated bilirubin increases due to the limited bacterial conversion of conjugated bilirubin to urobilin, allowing for increased deconjugation by beta-glucuronidase in the intestinal mucosa  (<a class="graphic graphic_figure graphicRef121543" href="/d/graphic/121543.html" rel="external">figure 1</a>). This further increasing the bilirubin load in the infant. (See <a class="local">'Bilirubin clearance and excretion'</a> above.)</p><p></p><p class="headingAnchor" id="H503254764"><span class="h1">PEAK TSB LEVELS AND TIME TO RESOLUTION</span><span class="headingEndMark"> — </span>Peak total serum or plasma bilirubin (TSB) and time to resolution vary by an infant's gestational age (GA), diet, and ethnicity/ancestry likely because of differences in hepatic uptake, clearance, and excretion [<a href="#rid4">4-6</a>]. Other important factors that impact the trajectory of neonatal hyperbilirubinemia include underlying hemolytic conditions (eg, alloimmune hemolytic disease, glucose-6-phosphate dehydrogenase deficiency) and individual vulnerability (eg, acute illness). (See  <a class="medical medical_review" href="/d/html/4994.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Risk factors'</a>.) </p><p>Newborns who do not follow the natural surge, plateau, and decline of TSB are most likely to require intervention. (See  <a class="medical medical_review" href="/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peak TSB</strong> – TSB levels peak at 48 to 96 hours of age, though in newborns of East Asian ancestry, the peak typically occurs between 72 and 120 hours of age. Mean peak TSB values typically range from 8 to 14 mg/dL (120 to 239 micromol/L). The 95<sup>th</sup> percentile is approximately 18 mg/dL (308 micromol/L) [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Time to resolution</strong> – Visible jaundice resolves within the first one to two weeks after birth. Clinical jaundice typically resolves by one week in formula-fed White and Black infants, and by the 10<sup>th</sup> day in Eastern Asian infants. Jaundice resolves by three weeks in approximately 65 percent of exclusively breastfed newborns, although approximately one in five are still jaundiced at four weeks of age [<a href="#rid8">8</a>]. Persistence of hyperbilirubinemia beyond one to two weeks of age is generally considered prolonged hyperbilirubinemia/jaundice and these infants require an assessment of their direct or conjugated bilirubin levels to rule out cholestatic jaundice [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/5941.html" rel="external">"Approach to evaluation of cholestasis in neonates and young infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nomograms from different populations</strong> – Studies using transcutaneous bilirubin devices have developed nomograms to define the range of hour-specific normal values and the<sup> </sup>75<sup>th</sup> and 95<sup>th</sup> percentiles according to postnatal age [<a href="#rid10">10-14</a>]. Many of the available studies were performed in populations that included predominantly breastfed White newborns. However, there are available data across different racial and ethnic groups and regions of the world [<a href="#rid10">10-23</a>]. All demonstrate an hourly progression to peak levels at ages 3 to 5 days and a transient plateau that is subsequently followed by decline. (See  <a class="medical medical_review" href="/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening", section on 'Nomograms in different populations'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of genetic polymorphisms</strong> – Differences in peak TSB levels and time needed for resolution may result in part from genetic variability in hepatic conjugating ability of bilirubin [<a href="#rid1">1</a>]. As an example, polymorphisms in the <em>UGT1A1</em> gene, due to differences in the number of thymine-adenine (TA) repeats or "TATA box" in the promoter region of the gene, vary among individuals of Eastern Asian, African, and European ancestries [<a href="#rid24">24</a>]. These polymorphisms correlate with decreases in UGT1A1 enzyme activity resulting in increased TSB levels and longer duration for resolution. (See  <a class="medical medical_review" href="/d/html/3578.html" rel="external">"Gilbert syndrome", section on 'Genetics'</a>.)</p><p></p><p class="bulletIndent1">Another cause of variation results from a common genetic variant in the <em>UGT1A1</em> gene at Gly71Arg (known as <em>UGT1A1*6</em> polymorphism) that occurs commonly in individuals of Eastern Asian ancestry. This polymorphism is associated with increased risk of severe neonatal hyperbilirubinemia (by approximately 20 percent) [<a href="#rid25">25,26</a>]. Other <em>UGT1A1</em> polymorphisms have also been identified (<em>UGT1A1*9</em>, <em>UGT1A1*16</em>, <em>UGT1A1*27</em>, and <em>UGT1A1*28</em>), but further work is needed to fully elucidate the impact of these mutations on an infant's risk for developing severe hyperbilirubinemia. </p><p></p><p class="headingAnchor" id="H7"><span class="h1">CAUSES OF SIGNIFICANT UNCONJUGATED NEONATAL HYPERBILIRUBINEMIA</span></p><p class="headingAnchor" id="H3205426273"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Hyperbilirubinemia can be caused by specific underlying pathologic conditions or by exaggerations of the mechanisms responsible for normal neonatal "physiologic jaundice" jaundice  (<a class="graphic graphic_figure graphicRef121543" href="/d/graphic/121543.html" rel="external">figure 1</a>). Identification of an underlying pathologic cause of neonatal hyperbilirubinemia is useful in determining whether therapeutic interventions are needed and timing of intervention to prevent severe hyperbilirubinemia [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/5063.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"</a>.)</p><p>Any increase in bilirubin load resulting in significant hyperbilirubinemia is due to either or both an increase in bilirubin production or a decrease in bilirubin clearance  (<a class="graphic graphic_figure graphicRef122901" href="/d/graphic/122901.html" rel="external">figure 3</a>). </p><p class="headingAnchor" id="H8"><span class="h2">Increased production</span><span class="headingEndMark"> — </span>The most common cause of clinically significant unconjugated hyperbilirubinemia is increased bilirubin production due to hemolytic disease processes, such as [<a href="#rid24">24,25,28-33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Isoimmune-mediated hemolysis (eg, ABO or Rh[D] incompatibility) [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/5933.html" rel="external">"Alloimmune hemolytic disease of the newborn: Postnatal diagnosis and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inherited red blood cell membrane defects (eg, hereditary spherocytosis and elliptocytosis). (See  <a class="medical medical_review" href="/d/html/7079.html" rel="external">"Hereditary spherocytosis"</a> and  <a class="medical medical_review" href="/d/html/7087.html" rel="external">"Hereditary elliptocytosis and related disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocyte enzymatic defects (eg, glucose-6-phosphate dehydrogenase [G6PD] deficiency [<a href="#rid35">35</a>], pyruvate kinase deficiency, and congenital erythropoietic porphyria). (See  <a class="medical medical_review" href="/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a> and  <a class="medical medical_review" href="/d/html/7129.html" rel="external">"Pyruvate kinase deficiency"</a> and  <a class="medical medical_review" href="/d/html/7102.html" rel="external">"Congenital erythropoietic porphyria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis – The mechanism is not known; however, one theory suggests that increased oxidative stress due to sepsis damages neonatal red blood cells [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other causes of increased bilirubin production due to increased red blood cell breakdown include polycythemia or sequestration of blood within a closed space, such as in cephalohematomas. (See  <a class="medical medical_review" href="/d/html/5940.html" rel="external">"Neonatal polycythemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Macrosomic infants of diabetic mothers (IDM) have increased bilirubin production due to either polycythemia or ineffective erythropoiesis. (See  <a class="medical medical_review" href="/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)"</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Decreased clearance</span><span class="headingEndMark"> — </span>Inherited defects in the gene that encodes the enzyme UGT1A1, which catalyzes the conjugation of bilirubin with glucuronic acid, decrease bilirubin conjugation. This reduces hepatic bilirubin clearance and increases total serum or plasma bilirubin (TSB) levels [<a href="#rid36">36</a>]. These disorders include Crigler-Najjar syndrome types I and II and Gilbert syndrome. These syndromes are briefly summarized below and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3569.html" rel="external">"Crigler-Najjar syndrome"</a> and  <a class="medical medical_review" href="/d/html/3578.html" rel="external">"Gilbert syndrome"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Crigler-Najjar syndrome</span><span class="headingEndMark"> — </span>There are two variants of Crigler-Najjar syndrome. (See  <a class="medical medical_review" href="/d/html/3569.html" rel="external">"Crigler-Najjar syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Crigler-Najjar syndrome type I (CN-I) – This is the most severe form of inherited UGT1A1 disorders. UGT1A1 activity is essentially absent, and severe hyperbilirubinemia develops in the first two to three days after birth. Lifelong phototherapy is required to avoid the development of bilirubin-induced neurologic dysfunction (BIND) unless liver transplantation is performed. The mode of inheritance is autosomal recessive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Crigler-Najjar syndrome type II (CN-II) – CN-II is less severe than is CN-I. UGT1A1 activity is low but detectable. Although some affected children develop severe jaundice, the hyperbilirubinemia often responds to <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a> treatment. CN-II usually is inherited in an autosomal recessive manner, although autosomal dominant transmission occurs in some cases.</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Gilbert syndrome</span><span class="headingEndMark"> — </span>Gilbert syndrome is the most common inherited disorder of bilirubin glucuronidation due to mutations in the <em>UGT1A1 </em>gene. In White and Black patients, it results from a mutation in the promoter region of t<em>he UGT1A1</em> gene [<a href="#rid37">37</a>]. The mutation causes a reduced production of UGT1A1, leading to unconjugated hyperbilirubinemia. In the Eastern Asian population, Gilbert syndrome results from a missense mutation in the coding area of th<em>e UGT1A1</em> gene [<a href="#rid25">25,38</a>]. Breast milk jaundice during the second week after birth may be due to the concurrent neonatal manifestation of Gilbert syndrome. (See <a class="local">'Breast milk jaundice'</a> below.)</p><p>In the United States, 9 percent of the population is homozygous and 42 percent heterozygous for the Gilbert mutation [<a href="#rid39">39</a>]. Newborns who are homozygous for the gene mutation have a higher incidence of developing hyperbilirubinemia during the first two days after birth than infants without the mutation or those who are heterozygous [<a href="#rid40">40</a>]. Similar findings have been noted in other parts of the world, especially in Eastern Asian countries [<a href="#rid26">26,41</a>]. There is also evidence that increased hemolysis contributes to neonatal hyperbilirubinemia in addition to the reduction in bilirubin conjugation [<a href="#rid42">42</a>]. </p><p>However, data from case series have reported that the Gilbert genotype alone is not sufficient to increase the incidence of hyperbilirubinemia [<a href="#rid43">43,44</a>]. Rather, the Gilbert genotype appears to only become clinically relevant when affected newborns have increased bilirubin production or enhanced enterohepatic circulation of bilirubin [<a href="#rid45">45,46</a>]. In particular, the combination of a Gilbert genotype with an underlying condition that increases TSB production, such as G6PD deficiency, is associated with severe or significant hyperbilirubinemia [<a href="#rid33">33,45,47</a>]. (See  <a class="medical medical_review" href="/d/html/3578.html" rel="external">"Gilbert syndrome"</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">OATP-2 polymorphism</span><span class="headingEndMark"> — </span>In addition to the polymorphisms of the <em>UGT1A1</em> discussed above, a study of Taiwanese newborns reported that those with a polymorphic variant of the organic anion transporter protein OATP-2 (also known as OATP-C or solute carrier organic anion transporter 1B1 [<em>SLCO1B1</em>]) were more likely to develop severe hyperbilirubinemia [<a href="#rid48">48</a>]. Furthermore, the combination of the <em>OATP-2</em> polymorphism with a <em>UGT1A1</em> gene mutation increased this risk.</p><p class="headingAnchor" id="H13"><span class="h3">Other causes of decreased clearance</span><span class="headingEndMark"> — </span>Other causes of decreased bilirubin clearance include maternal diabetes [<a href="#rid49">49</a>], congenital hypothyroidism, galactosemia, and panhypopituitarism, although in the latter two conditions, infants typically present with elevated conjugated hyperbilirubinemia. These disorders usually are identified by metabolic screening programs; however, infants may develop severe and prolonged jaundice before screening results become available. (See  <a class="medical medical_review" href="/d/html/5836.html" rel="external">"Clinical features and detection of congenital hypothyroidism"</a> and  <a class="medical medical_review" href="/d/html/2928.html" rel="external">"Galactosemia: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Increased enterohepatic circulation of bilirubin</span><span class="headingEndMark"> — </span>Causes of hyperbilirubinemia due to increased enterohepatic circulation of bilirubin include impaired intestinal motility caused by functional or anatomic obstruction and possibly breast milk jaundice, but the underlying mechanisms of the latter has not been confirmed.</p><p class="headingAnchor" id="H15"><span class="h3">Breast milk jaundice</span><span class="headingEndMark"> — </span>Breast milk jaundice is defined as the persistence of benign neonatal hyperbilirubinemia beyond the first two to three weeks of age. It typically presents after the first three to five days of life, peaks within two weeks after birth, and progressively declines to normal levels over 3 to 12 weeks [<a href="#rid8">8,50</a>]. Breast milk jaundice needs to be distinguished from breastfeeding (lactation) failure jaundice, the latter is due to suboptimal fluid and caloric intake during the first seven days of life. (See <a class="local">'Inadequate milk intake'</a> below.)</p><p>In infants with jaundice who exclusively receive human milk, TSB levels &gt;5 mg/dL (86 micromol/L) often persist for several weeks after delivery [<a href="#rid8">8</a>]. Although the hyperbilirubinemia is generally mild and typically does not require intervention, it should be monitored to ensure that it remains in the unconjugated form and does not increase. If TSB levels begin to increase or there is a significant component of conjugated bilirubin, evaluation for other causes of hyperbilirubinemia should be performed. In the case of elevated conjugated bilirubin, causes of cholestasis need to be considered. If after evaluation human milk intake is the only remaining viable factor, human milk feeding can continue if the TSB remains in a safe zone with the expectation of resolution by 12 weeks of age [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/5008.html" rel="external">"Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening"</a> and  <a class="medical medical_review" href="/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a> and  <a class="medical medical_review" href="/d/html/5941.html" rel="external">"Approach to evaluation of cholestasis in neonates and young infants"</a>.)</p><p>The underlying mechanism of "breast milk jaundice" is not fully known. Human milk contains high concentrations of beta-glucuronidase, which catalyzes the hydrolysis of beta-D-glucuronic acid [<a href="#rid52">52</a>]. In contrast, there is negligible amounts of beta-glucuronidase in infant formula, and formula-fed infants have lower levels of bilirubin than those who receive human milk [<a href="#rid53">53,54</a>]. For breast milk-fed infants, the loss of beta-D-glucuronic acid due to increased degradation is thought to promote an increase in intestinal absorption of unconjugated bilirubin [<a href="#rid52">52</a>]  (<a class="graphic graphic_figure graphicRef121543" href="/d/graphic/121543.html" rel="external">figure 1</a>). Beta-glucuronidase inhibitors, such as enzymatically-hydrolyzed casein or L-aspartic acid, which is contained in casein hydrolysate formula, have been used prophylactically in breastfed newborns [<a href="#rid55">55</a>]. However, the prolonged unconjugated hyperbilirubinemia associated with human milk is benign, and there appears to be no benefit for the use of these agents [<a href="#rid56">56</a>]. As a result, we do not recommend these agents for treating breast milk jaundice.</p><p>Another potential underlying mechanism is polymorphic mutation of the <em>UGT1A1</em> gene. In a Japanese study of 170 neonates with breast milk jaundice, half of infants were homozygous for the <em>UGT1A1*6</em> genotype [<a href="#rid57">57</a>]. These infants had higher TSB levels than infants with other polymorphisms. The <em>UGT1A1*6</em> genotype was not detected in control infants. However, further studies in other areas of the world are needed to determine whether there is a causal relationship between genetic variation of the <em>UGT1A1</em> gene and breast milk jaundice. Thus, currently genetic testing should not be used in the evaluation of breast milk-related jaundice.</p><p class="headingAnchor" id="H16"><span class="h3">Ileus or intestinal obstruction</span><span class="headingEndMark"> — </span>Ileus or anatomic causes of intestinal obstruction increase the enterohepatic circulation of bilirubin and result in hyperbilirubinemia. TSB levels are frequently higher with small bowel than with large bowel obstructions. As an example, hyperbilirubinemia occurs in 10 to 25 percent of infants with pyloric stenosis when vomiting begins. (See  <a class="medical medical_review" href="/d/html/5890.html" rel="external">"Infantile hypertrophic pyloric stenosis", section on 'Clinical associations'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Inadequate milk intake</span><span class="headingEndMark"> — </span>Breastfeeding difficulties are common during the first week after birth. These difficulties can lead to inadequate intake of fluids and calories resulting in hypovolemia and significant weight loss. This results in hyperbilirubinemia (jaundice) and, in some cases, hypernatremia (serum sodium &gt;150 mEq/L). Inadequate intake also causes slower bilirubin elimination and increases enterohepatic circulation of bilirubin that contribute to an elevated TSB level. (See  <a class="medical medical_review" href="/d/html/4996.html" rel="external">"Common problems of breastfeeding and weaning", section on 'Inadequate milk intake'</a> and  <a class="medical medical_review" href="/d/html/4986.html" rel="external">"Initiation of breastfeeding", section on 'Assessment of intake'</a>.)</p><p>Maternal breastfeeding complications (eg, engorgement, cracked nipples, and fatigue) compounded by neonatal factors (eg, ineffective suck), can contribute to ineffective breastfeeding if they are not properly addressed prior to hospital discharge. (See  <a class="medical medical_review" href="/d/html/4996.html" rel="external">"Common problems of breastfeeding and weaning"</a>.)</p><p>Late preterm infants (defined as gestational age [GA] between 34 and 36 weeks and 6 days) are more likely to experience difficulty in establishing successful breastfeeding than term infants. Late preterm infants may not fully empty the breast because of increased sleepiness, fatigue, and/or difficulty maintaining a latch because their oro-buccal coordination and swallowing mechanisms are not fully matured. As a result, additional support and close monitoring are warranted for this group of infants and their mothers. (See  <a class="medical medical_review" href="/d/html/5035.html" rel="external">"Breastfeeding the preterm infant", section on 'Late preterm infants'</a>.)</p><p>Establishment of successful breastfeeding, one of the mainstays of preventing hyperbilirubinemia, is challenging due to shortened postpartum length of stay for newborn infants and their mothers. Postnatal education, support, and care should be provided to the infant-mother dyad during the birth hospitalization and after discharge and is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/4978.html" rel="external">"Breastfeeding: Parental education and support"</a> and  <a class="medical medical_review" href="/d/html/4986.html" rel="external">"Initiation of breastfeeding"</a>.)</p><p class="headingAnchor" id="H65076758"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116513.html" rel="external">"Society guideline links: Neonatal jaundice"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1203.html" rel="external">"Patient education: Jaundice in newborn infants (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance</strong> – Nearly all term and near-term newborn infants develop elevated bilirubin levels after birth. Infants with severe hyperbilirubinemia (defined as total serum or plasma bilirubin [TSB] &gt;25 mg/dL [428 micromol/L]) are at risk for developing bilirubin-induced neurologic dysfunction (BIND). (See <a class="local">'Definitions'</a> above and  <a class="medical medical_review" href="/d/html/4994.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Risk factors, clinical manifestations, and neurologic complications", section on 'Consequences of severe hyperbilirubinemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign hyperbilirubinemia</strong> – Benign neonatal hyperbilirubinemia, previously referred to as "physiologic jaundice," is a normal transitional phenomenon caused by the turnover of fetal red blood cells, immaturity of the newborn's liver to efficiently metabolize bilirubin, and sterile newborn gut, resulting in decreased bilirubin clearance and increased enterohepatic circulation  (<a class="graphic graphic_figure graphicRef121543" href="/d/graphic/121543.html" rel="external">figure 1</a>). It typically presents as mild unconjugated hyperbilirubinemia. TSB levels usually peak at 48 to 96 hours of age, though in newborns of East Asian ancestry, the peak typically occurs between 72 and 120 hours of age. Mean peak TSB values typically range from 8 to 14 mg/dL (120 to 239 micromol/L). Visible jaundice resolves within the first one to two weeks after birth. (See <a class="local">'Benign neonatal hyperbilirubinemia'</a> above and <a class="local">'Peak TSB levels and time to resolution'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of neonatal hyperbilirubinemia</strong> – Hyperbilirubinemia is due to increased bilirubin load either due to an increase in bilirubin production or decrease in clearance, or both  (<a class="graphic graphic_figure graphicRef122901" href="/d/graphic/122901.html" rel="external">figure 3</a>). (See <a class="local">'Increased production'</a> above and <a class="local">'Decreased clearance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of clinically significant hyperbilirubinemia</strong> – For infants with clinically significant hyperbilirubinemia, identification of the underlying cause is useful in determining the need for and timing of therapeutic interventions. (See <a class="local">'Causes of significant unconjugated neonatal hyperbilirubinemia'</a> above.)</p><p></p><p class="bulletIndent1">Causes of significant unconjugated neonatal hyperbilirubinemia can be classified by pathogenesis as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Increased production</strong> of bilirubin (see <a class="local">'Increased production'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hemolytic disease (see  <a class="medical medical_review" href="/d/html/5933.html" rel="external">"Alloimmune hemolytic disease of the newborn: Postnatal diagnosis and management"</a> and  <a class="medical medical_review" href="/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Polycythemia (see  <a class="medical medical_review" href="/d/html/5940.html" rel="external">"Neonatal polycythemia"</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Cephalohematoma (see  <a class="medical medical_review" href="/d/html/5031.html" rel="external">"Neonatal birth injuries", section on 'Cephalohematoma'</a>)</p><p class="bulletIndent3"><span class="glyph">-</span>Sepsis (see  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates"</a>) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Increased enterohepatic circulation</strong> of bilirubin (see <a class="local">'Increased enterohepatic circulation of bilirubin'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Breast milk jaundice (see <a class="local">'Breast milk jaundice'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Impaired intestinal motility (ileus or obstruction)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inadequate intake of breast milk</strong> due to breastfeeding difficulties resulting in hypovolemia and inadequate caloric intake. (See  <a class="medical medical_review" href="/d/html/4996.html" rel="external">"Common problems of breastfeeding and weaning", section on 'Inadequate milk intake'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med 2001; 344:581.</a></li><li class="breakAll">Maisels MJ. Neonatal hyperbilirubinemia. In: Care of the High-Risk Neonate, 5th ed, Klaus MH, Fanaroff AA (Eds), WB Saunders, Philadelphia 2001. p.324.</li><li><a class="nounderline abstract_t">Kawade N, Onishi S. The prenatal and postnatal development of UDP-glucuronyltransferase activity towards bilirubin and the effect of premature birth on this activity in the human liver. Biochem J 1981; 196:257.</a></li><li><a class="nounderline abstract_t">Shibuya A, Itoh T, Tukey RH, Fujiwara R. Impact of fatty acids on human UDP-glucuronosyltransferase 1A1 activity and its expression in neonatal hyperbilirubinemia. Sci Rep 2013; 3:2903.</a></li><li><a class="nounderline abstract_t">Fujiwara R, Chen S, Karin M, Tukey RH. Reduced expression of UGT1A1 in intestines of humanized UGT1 mice via inactivation of NF-κB leads to hyperbilirubinemia. Gastroenterology 2012; 142:109.</a></li><li><a class="nounderline abstract_t">Fujiwara R, Maruo Y, Chen S, Tukey RH. Role of extrahepatic UDP-glucuronosyltransferase 1A1: Advances in understanding breast milk-induced neonatal hyperbilirubinemia. Toxicol Appl Pharmacol 2015; 289:124.</a></li><li><a class="nounderline abstract_t">Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999; 103:6.</a></li><li><a class="nounderline abstract_t">Maisels MJ, Clune S, Coleman K, et al. The natural history of jaundice in predominantly breastfed infants. Pediatrics 2014; 134:e340.</a></li><li><a class="nounderline abstract_t">Fawaz R, Baumann U, Ekong U, et al. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2017; 64:154.</a></li><li><a class="nounderline abstract_t">Maisels MJ, Kring E. Transcutaneous bilirubin levels in the first 96 hours in a normal newborn population of &gt; or = 35 weeks' gestation. Pediatrics 2006; 117:1169.</a></li><li><a class="nounderline abstract_t">Kaplan M, Maisels MJ. Natural history of early neonatal bilirubinemia: a global perspective. J Perinatol 2021; 41:873.</a></li><li><a class="nounderline abstract_t">Varvarigou A, Fouzas S, Skylogianni E, et al. Transcutaneous bilirubin nomogram for prediction of significant neonatal hyperbilirubinemia. Pediatrics 2009; 124:1052.</a></li><li><a class="nounderline abstract_t">De Luca D, Romagnoli C, Tiberi E, et al. Skin bilirubin nomogram for the first 96 h of life in a European normal healthy newborn population, obtained with multiwavelength transcutaneous bilirubinometry. Acta Paediatr 2008; 97:146.</a></li><li><a class="nounderline abstract_t">Fouzas S, Mantagou L, Skylogianni E, et al. Transcutaneous bilirubin levels for the first 120 postnatal hours in healthy neonates. Pediatrics 2010; 125:e52.</a></li><li><a class="nounderline abstract_t">Kaplan M, Bromiker R. Variation in Transcutaneous Bilirubin Nomograms across Population Groups. J Pediatr 2019; 208:273.</a></li><li><a class="nounderline abstract_t">Engle WD, Lai S, Ahmad N, et al. An hour-specific nomogram for transcutaneous bilirubin values in term and late preterm Hispanic neonates. Am J Perinatol 2009; 26:425.</a></li><li><a class="nounderline abstract_t">Sanpavat S, Nuchprayoon I, Smathakanee C, Hansuebsai R. Nomogram for prediction of the risk of neonatal hyperbilirubinemia, using transcutaneous bilirubin. J Med Assoc Thai 2005; 88:1187.</a></li><li><a class="nounderline abstract_t">Bental YA, Shiff Y, Dorsht N, et al. Bhutani-based nomograms for the prediction of significant hyperbilirubinaemia using transcutaneous measurements of bilirubin. Acta Paediatr 2009; 98:1902.</a></li><li><a class="nounderline abstract_t">Yu ZB, Dong XY, Han SP, et al. Transcutaneous bilirubin nomogram for predicting neonatal hyperbilirubinemia in healthy term and late-preterm Chinese infants. Eur J Pediatr 2011; 170:185.</a></li><li><a class="nounderline abstract_t">Akahira-Azuma M, Yonemoto N, Mori R, et al. An hour-specific transcutaneous bilirubin nomogram for Mongolian neonates. Eur J Pediatr 2015; 174:1299.</a></li><li><a class="nounderline abstract_t">Han S, Yu Z, Liu L, et al. A Model for Predicting Significant Hyperbilirubinemia in Neonates From China. Pediatrics 2015; 136:e896.</a></li><li><a class="nounderline abstract_t">Bromiker R, Goldberg A, Kaplan M. Israel transcutaneous bilirubin nomogram predicts significant hyperbilirubinemia. J Perinatol 2017; 37:1315.</a></li><li><a class="nounderline abstract_t">Engle WD, Jackson GL, Sendelbach D, et al. Assessment of a transcutaneous device in the evaluation of neonatal hyperbilirubinemia in a primarily Hispanic population. Pediatrics 2002; 110:61.</a></li><li><a class="nounderline abstract_t">Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998; 95:8170.</a></li><li><a class="nounderline abstract_t">Akaba K, Kimura T, Sasaki A, et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int 1998; 46:21.</a></li><li><a class="nounderline abstract_t">Long J, Zhang S, Fang X, et al. Neonatal hyperbilirubinemia and Gly71Arg mutation of UGT1A1 gene: a Chinese case-control study followed by systematic review of existing evidence. Acta Paediatr 2011; 100:966.</a></li><li><a class="nounderline abstract_t">Kemper AR, Newman TB, Slaughter JL, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics 2022; 150.</a></li><li class="breakAll">Kaplan M, Wong RJ, Sibley E, Stevenson DK. Neonatal jaundice and liver disease. In: Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant, 9th ed, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier Mosby, St. Louis 2011. Vol 2, p.1443.</li><li><a class="nounderline abstract_t">MacDonald MG. Hidden risks: early discharge and bilirubin toxicity due to glucose 6-phosphate dehydrogenase deficiency. Pediatrics 1995; 96:734.</a></li><li><a class="nounderline abstract_t">Slusher TM, Vreman HJ, McLaren DW, et al. Glucose-6-phosphate dehydrogenase deficiency and carboxyhemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants. J Pediatr 1995; 126:102.</a></li><li><a class="nounderline abstract_t">Johnson JD, Angelus P, Aldrich M, Skipper BJ. Exaggerated jaundice in Navajo neonates. The role of bilirubin production. Am J Dis Child 1986; 140:889.</a></li><li><a class="nounderline abstract_t">Fischer AF, Nakamura H, Uetani Y, et al. Comparison of bilirubin production in Japanese and Caucasian infants. J Pediatr Gastroenterol Nutr 1988; 7:27.</a></li><li><a class="nounderline abstract_t">Watchko JF, Lin Z, Clark RH, et al. Complex multifactorial nature of significant hyperbilirubinemia in neonates. Pediatrics 2009; 124:e868.</a></li><li><a class="nounderline abstract_t">Kaplan M, Hammerman C, Vreman HJ, et al. Direct antiglobulin titer strength and hyperbilirubinemia. Pediatrics 2014; 134:e1340.</a></li><li><a class="nounderline abstract_t">Riskin A, Gery N, Kugelman A, et al. Glucose-6-phosphate dehydrogenase deficiency and borderline deficiency: association with neonatal hyperbilirubinemia. J Pediatr 2012; 161:191.</a></li><li><a class="nounderline abstract_t">Skierka JM, Kotzer KE, Lagerstedt SA, et al. UGT1A1 genetic analysis as a diagnostic aid for individuals with unconjugated hyperbilirubinemia. J Pediatr 2013; 162:1146.</a></li><li><a class="nounderline abstract_t">Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333:1171.</a></li><li><a class="nounderline abstract_t">Maruo Y, Nishizawa K, Sato H, et al. Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Pediatrics 1999; 103:1224.</a></li><li><a class="nounderline abstract_t">Kadakol A, Sappal BS, Ghosh SS, et al. Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus. J Med Genet 2001; 38:244.</a></li><li><a class="nounderline abstract_t">Bancroft JD, Kreamer B, Gourley GR. Gilbert syndrome accelerates development of neonatal jaundice. J Pediatr 1998; 132:656.</a></li><li><a class="nounderline abstract_t">Chang PF, Lin YC, Liu K, et al. Prolonged unconjugated hyperbiliriubinemia in breast-fed male infants with a mutation of uridine diphosphate-glucuronosyl transferase. J Pediatr 2009; 155:860.</a></li><li><a class="nounderline abstract_t">Kaplan M, Hammerman C, Rubaltelli FF, et al. Hemolysis and bilirubin conjugation in association with UDP-glucuronosyltransferase 1A1 promoter polymorphism. Hepatology 2002; 35:905.</a></li><li><a class="nounderline abstract_t">Travan L, Lega S, Crovella S, et al. Severe neonatal hyperbilirubinemia and UGT1A1 promoter polymorphism. J Pediatr 2014; 165:42.</a></li><li><a class="nounderline abstract_t">Petersen JP, Henriksen TB, Hollegaard MV, et al. Extreme neonatal hyperbilirubinemia and a specific genotype: a population-based case-control study. Pediatrics 2014; 134:510.</a></li><li><a class="nounderline abstract_t">Kaplan M, Renbaum P, Levy-Lahad E, et al. Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia. Proc Natl Acad Sci U S A 1997; 94:12128.</a></li><li><a class="nounderline abstract_t">Kaplan M, Renbaum P, Vreman HJ, et al. (TA)n UGT 1A1 promoter polymorphism: a crucial factor in the pathophysiology of jaundice in G-6-PD deficient neonates. Pediatr Res 2007; 61:727.</a></li><li><a class="nounderline abstract_t">Watchko JF. Vigintiphobia revisited. Pediatrics 2005; 115:1747.</a></li><li><a class="nounderline abstract_t">Huang MJ, Kua KE, Teng HC, et al. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res 2004; 56:682.</a></li><li><a class="nounderline abstract_t">Stevenson DK, Ostrander CR, Hopper AO, et al. Pulmonary excretion of carbon monoxide as an index of bilirubin production. IIa. Evidence for possible delayed clearance of bilirubin in infants of diabetic mothers. J Pediatr 1981; 98:822.</a></li><li><a class="nounderline abstract_t">Grunebaum E, Amir J, Merlob P, et al. Breast mild jaundice: natural history, familial incidence and late neurodevelopmental outcome of the infant. Eur J Pediatr 1991; 150:267.</a></li><li><a class="nounderline abstract_t">Preer GL, Philipp BL. Understanding and managing breast milk jaundice. Arch Dis Child Fetal Neonatal Ed 2011; 96:F461.</a></li><li><a class="nounderline abstract_t">Gourley GR, Arend RA. beta-Glucuronidase and hyperbilirubinaemia in breast-fed and formula-fed babies. Lancet 1986; 1:644.</a></li><li><a class="nounderline abstract_t">Gourley GR, Kreamer B, Arend R. The effect of diet on feces and jaundice during the first 3 weeks of life. Gastroenterology 1992; 103:660.</a></li><li><a class="nounderline abstract_t">Gourley GR, Kreamer B, Cohnen M, Kosorok MR. Neonatal jaundice and diet. Arch Pediatr Adolesc Med 1999; 153:184.</a></li><li><a class="nounderline abstract_t">Gourley GR, Li Z, Kreamer BL, Kosorok MR. A controlled, randomized, double-blind trial of prophylaxis against jaundice among breastfed newborns. Pediatrics 2005; 116:385.</a></li><li><a class="nounderline abstract_t">Bhutani VK. Abuse of casein hydrolysate formulas for treating infants with severe hyperbilirubinemia. Pediatrics 2006; 117:2317; author reply 2317.</a></li><li><a class="nounderline abstract_t">Maruo Y, Morioka Y, Fujito H, et al. Bilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice. J Pediatr 2014; 165:36.</a></li></ol></div><div id="topicVersionRevision">Topic 5020 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11207355" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Neonatal hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11207355" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neonatal hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6796071" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The prenatal and postnatal development of UDP-glucuronyltransferase activity towards bilirubin and the effect of premature birth on this activity in the human liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24104695" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Impact of fatty acids on human UDP-glucuronosyltransferase 1A1 activity and its expression in neonatal hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21983082" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Reduced expression of UGT1A1 in intestines of humanized UGT1 mice via inactivation of NF-κB leads to hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26342858" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Role of extrahepatic UDP-glucuronosyltransferase 1A1: Advances in understanding breast milk-induced neonatal hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9917432" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25049352" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The natural history of jaundice in predominantly breastfed infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27429428" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585312" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Transcutaneous bilirubin levels in the first 96 hours in a normal newborn population of&gt;or = 35 weeks' gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33398058" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Natural history of early neonatal bilirubinemia: a global perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786443" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Transcutaneous bilirubin nomogram for prediction of significant neonatal hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18254903" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Skin bilirubin nomogram for the first 96 h of life in a European normal healthy newborn population, obtained with multiwavelength transcutaneous bilirubinometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008429" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Transcutaneous bilirubin levels for the first 120 postnatal hours in healthy neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30853197" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Variation in Transcutaneous Bilirubin Nomograms across Population Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19263335" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : An hour-specific nomogram for transcutaneous bilirubin values in term and late preterm Hispanic neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16536103" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nomogram for prediction of the risk of neonatal hyperbilirubinemia, using transcutaneous bilirubin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19508300" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bhutani-based nomograms for the prediction of significant hyperbilirubinaemia using transcutaneous measurements of bilirubin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20814696" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Transcutaneous bilirubin nomogram for predicting neonatal hyperbilirubinemia in healthy term and late-preterm Chinese infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25869495" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : An hour-specific transcutaneous bilirubin nomogram for Mongolian neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26391945" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A Model for Predicting Significant Hyperbilirubinemia in Neonates From China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29192695" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Israel transcutaneous bilirubin nomogram predicts significant hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12093947" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Assessment of a transcutaneous device in the evaluation of neonatal hyperbilirubinemia in a primarily Hispanic population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9653159" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9784835" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21272068" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Neonatal hyperbilirubinemia and Gly71Arg mutation of UGT1A1 gene: a Chinese case-control study followed by systematic review of existing evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35927462" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35927462" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7567340" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hidden risks: early discharge and bilirubin toxicity due to glucose 6-phosphate dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7815196" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Glucose-6-phosphate dehydrogenase deficiency and carboxyhemoglobin concentrations associated with bilirubin-related morbidity and death in Nigerian infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3739997" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Exaggerated jaundice in Navajo neonates. The role of bilirubin production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3335981" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparison of bilirubin production in Japanese and Caucasian infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858149" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Complex multifactorial nature of significant hyperbilirubinemia in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25332496" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Direct antiglobulin titer strength and hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22459229" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Glucose-6-phosphate dehydrogenase deficiency and borderline deficiency: association with neonatal hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23290513" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : UGT1A1 genetic analysis as a diagnostic aid for individuals with unconjugated hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7565971" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10353933" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11370628" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9580766" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Gilbert syndrome accelerates development of neonatal jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19683255" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prolonged unconjugated hyperbiliriubinemia in breast-fed male infants with a mutation of uridine diphosphate-glucuronosyl transferase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11915038" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hemolysis and bilirubin conjugation in association with UDP-glucuronosyltransferase 1A1 promoter polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24726540" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Severe neonatal hyperbilirubinemia and UGT1A1 promoter polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25092941" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Extreme neonatal hyperbilirubinemia and a specific genotype: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9342374" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426648" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : (TA)n UGT 1A1 promoter polymorphism: a crucial factor in the pathophysiology of jaundice in G-6-PD deficient neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930239" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Vigintiphobia revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319464" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Risk factors for severe hyperbilirubinemia in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7229770" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pulmonary excretion of carbon monoxide as an index of bilirubin production. IIa. Evidence for possible delayed clearance of bilirubin in infants of diabetic mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2029918" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Breast mild jaundice: natural history, familial incidence and late neurodevelopmental outcome of the infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20688866" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Understanding and managing breast milk jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2869347" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : beta-Glucuronidase and hyperbilirubinaemia in breast-fed and formula-fed babies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1634081" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The effect of diet on feces and jaundice during the first 3 weeks of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9988249" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Neonatal jaundice and diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16061593" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A controlled, randomized, double-blind trial of prophylaxis against jaundice among breastfed newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16740882" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Abuse of casein hydrolysate formulas for treating infants with severe hyperbilirubinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24650397" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Bilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
